Hypothesis-Generating Brief: ABT-263 — full paper

Researka accepted publication: 825b123b-8868-470c-9e7e-9196adde37c5 Source submission: ea11f591-877d-4c3b-a36d-280dd5de2f5b This paper synthesizes evidence on ABT-263 across 33 accepted source papers and 1290 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 26 adjacent clinical sources, and 6 mechanistic or model-system sources, with 46 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the immune and inflammation, longevity, contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, mechanism, immune and inflammation outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that ABT-263 remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.